In 2015, Illinois native Rob Besecker hiked to the base camp of Mount Everest, an impressive physical feat that only a few thousand achieve in a given year. Reaching this campsite 17,500 feet above sea level is a grueling challenge that requires weeks of hiking through rough terrain and thin air. Yet for Rob, 43, . . .
For IAFF member Ted Edwards, Fill The Boot is very personal: his wife Jamie lives with myotonic dystrophy.
Learn more about researcher Johanna Hamel’s clinical research training fellowship.
Johanna Hamel, M.D., received an MDA co-sponsored Clinical Research Training Fellowship for her work studying myotonic dystrophy (DM).
The investigational drug AMO-02 (tideglusib) has received FDA fast track designation for the treatment of DM1.
In the decades since Leslie Krongold’s mother died at the age of 56, she has learned that they likely shared a neuromuscular disease — myotonic dystrophy — and, as Leslie approaches her own 56th birthday next year, she feels more committed than ever to defying the odds her my mother couldn’t.
Almost exactly one year ago, in the spring of 2016, Kade McCann learned he had myotonic dystrophy. For this young athlete, the diagnosis stopped him in his tracks.
MDA Team Momentum is recruiting participants! If you’re on the fence about running, check out what motivates these five Team Momentum athletes.
Over 500 of the sharpest minds in research have gathered at MDA’s Scientific Conference as they work to unlock the secrets of neuromuscular diseases.
On Dec. 23, 2016 the FDA approved Spinraza for the treatment of SMA. In clinical trials to test Spinraza, participants who received treatment with the drug experienced life-changing outcomes they wouldn’t have been expected to achieve.
